Medivir AB (OSTO:MVIR) Cyclically Adjusted Book per Share: kr10.76 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MVIR Medivir AB OSTO:MVIR
50 GF Score
Price kr1.80
GF Value kr1.11
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medivir AB Cyclically Adjusted Book per Share?

Medivir AB OSTO:MVIR -1.10% 50 Cyclically Adjusted Book per Share is kr10.76 as of Mar. 2026. GuruFocus rates OSTO:MVIR with a GF Score™ of 50/100 and a GF Value™ of kr1.11 (Significantly Overvalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Medivir AB's adjusted book value per share for the three months ended in Mar. 2026 was kr0.355. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr10.76 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Medivir AB's average Cyclically Adjusted Book Growth Rate was -30.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -18.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Medivir AB was 0.10% per year. The lowest was -18.90% per year. And the median was -3.10% per year.

As of today (2026-08-04), Medivir AB's current stock price is kr1.80. Medivir AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was kr10.76. Medivir AB's Cyclically Adjusted PB Ratio of today is 0.17.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Medivir AB was 2.89. The lowest was 0.03. And the median was 0.31.


Medivir AB  (OSTO:MVIR) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Medivir AB's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.80/10.76
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Medivir AB was 2.89. The lowest was 0.03. And the median was 0.31.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Medivir AB Cyclically Adjusted Book per Share Related Terms


Medivir AB Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Medivir AB's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medivir AB Cyclically Adjusted Book per Share Chart

Medivir AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.93 22.34 21.06 16.75 11.92

Medivir AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.55 14.40 13.14 11.92 10.76

OSTO:MVIR vs VRTX, REGN, RVMD: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Medivir AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Medivir AB's Cyclically Adjusted PB Ratio falls into.


OSTO:MVIR
50GF Score
Medivir AB OSTO:MVIR
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medivir AB Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medivir AB's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.355/133.5600*133.5600
=0.355

Current CPI (Mar. 2026) = 133.5600.

Medivir AB Quarterly Data

Book Value per Share CPI Adj_Book
201606 34.786 101.019 45.991
201609 33.264 101.138 43.928
201612 43.631 102.022 57.119
201703 26.391 102.022 34.549
201706 23.281 102.752 30.261
201709 20.611 103.279 26.654
201712 17.160 103.793 22.081
201803 16.239 103.962 20.862
201806 13.677 104.875 17.418
201809 11.702 105.679 14.789
201812 8.524 105.912 10.749
201903 6.975 105.886 8.798
201906 6.631 106.742 8.297
201909 5.996 107.214 7.469
201912 5.111 107.766 6.334
202003 4.461 106.563 5.591
202006 4.105 107.498 5.100
202009 4.235 107.635 5.255
202012 3.932 108.296 4.849
202103 4.923 108.360 6.068
202106 4.670 108.928 5.726
202109 4.482 110.338 5.425
202112 4.134 112.486 4.908
202203 3.652 114.825 4.248
202206 3.312 118.384 3.737
202209 3.095 122.296 3.380
202212 2.834 126.365 2.995
202303 2.557 127.042 2.688
202306 2.170 129.407 2.240
202309 1.827 130.224 1.874
202312 2.085 131.912 2.111
202403 1.888 132.205 1.907
202406 1.569 132.716 1.579
202409 1.264 132.304 1.276
202412 1.030 132.987 1.034
202503 0.915 132.825 0.920
202506 0.710 133.699 0.709
202509 0.582 133.480 0.582
202512 0.346 133.390 0.346
202603 0.355 133.560 0.355

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of kr10.76 mean?
Medivir AB (OSTO:MVIR) has a Cyclically Adjusted Book per Share of kr10.76 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Medivir AB and its competitors.
Is Medivir AB's Cyclically Adjusted Book per Share too high?
Medivir AB's current Cyclically Adjusted Book per Share is kr10.76. Overall, Medivir AB has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medivir AB's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Medivir AB's Cyclically Adjusted Book per Share of kr10.76 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Medivir AB and its competitors. Medivir AB's current Cyclically Adjusted Book per Share is kr10.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medivir AB stock overvalued right now?
Based on GuruFocus' analysis, Medivir AB (OSTO:MVIR) is currently considered Significantly Overvalued. The stock's GF Value™ is kr1.11, compared to a current price of kr1.80 — trading 62.2% above its estimated fair value. The current Cyclically Adjusted Book per Share is kr10.76. Medivir AB's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Medivir AB (OSTO:MVIR), the current Cyclically Adjusted Book per Share is kr10.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medivir AB (OSTO:MVIR) Overvalued in 2026?

Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued. The current stock price of kr1.80 is trading 62.2% above its estimated GF Value™ of kr1.11. GuruFocus considers Medivir AB to be Significantly Overvalued.

Key valuation signals for OSTO:MVIR:

  • Cyclically Adjusted Book per Share: kr10.76
  • GF Value™: kr1.11 vs. price of kr1.80 (62.2% above fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the OSTO:MVIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medivir AB Business Description

Other Exchanges MVIRs:UK0GP7:UKMVR0:Germany
Address Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
50GF Score

Get the complete analysis for OSTO:MVIR

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.80
Price
kr1.11
GF Value